MEDANTA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.4

📊 Analysis: MEDANTA shows weak-to-moderate intraday potential. Current price (₹1,171) is below both the 50 DMA (₹1,234) and 200 DMA (₹1,248), reflecting short-term weakness. RSI at 36.7 indicates oversold territory, which could trigger a technical bounce, but MACD (-30.9) confirms bearish momentum. Volume (1.99 lakh) is above the weekly average (1.54 lakh), showing active participation. Strong fundamentals (ROCE 19.6%, ROE 15.2%) provide support, but high P/E (60.0) raises valuation concerns.

💡 Optimal Buy Price: ₹1,165–₹1,175 (near support zone).

🎯 Profit Exit Levels: ₹1,195 (first resistance), ₹1,215 (second resistance).

🛡️ Stop-Loss: ₹1,150 (below intraday support).

⏱️ If Already Holding: Exit intraday if price fails to sustain above ₹1,171 or if MACD continues bearish. Consider booking profits near ₹1,195–₹1,215 if momentum improves during the session.

Positive

• 📈 ROCE (19.6%) and ROE (15.2%) highlight strong capital efficiency.
• 💰 Low debt-to-equity (0.07) ensures financial stability.
• 📊 DII holding increased (+0.77%), showing domestic investor confidence.
• 📈 Quarterly PAT growth from ₹137 Cr. to ₹128 Cr. with 22.6% variation.

Limitation

• ⚠️ MACD negative (-30.9) indicates strong bearish momentum.
• 📉 Current price below DMA levels reflects short-term weakness.
• 📊 High P/E (60.0) compared to industry average (51.8), suggesting overvaluation.
• 🌍 FII holding decreased (-0.13%), showing foreign investor caution.
• 📉 Dividend yield (0.04%) provides limited shareholder returns.

Company Negative News

• 📰 No major negative news reported, but technical weakness and high valuation weigh on sentiment.

Company Positive News

• 📰 Strong fundamentals with ROCE and ROE support long-term confidence.
• 📊 DII inflows add confidence to fundamentals despite weak technicals.

Industry

• 🏭 Healthcare sector trading at PE 51.8, slightly lower than MEDANTA’s valuation (60.0).
• 📈 Industry demand supported by rising healthcare spending and hospital expansion.

Conclusion

⚖️ MEDANTA is fundamentally strong with efficient capital use and institutional support, but intraday signals are weak due to bearish MACD and price below DMA levels. Cautious entry near ₹1,165–₹1,175 with profit exits at ₹1,195–₹1,215 is possible, while maintaining a strict stop-loss at ₹1,150.

Would you like me to extend this into a peer benchmarking overlay comparing MEDANTA with other hospital and healthcare service providers, or should we focus on basket rotation signals for intraday workflow optimization?